These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25684180)

  • 21. High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients.
    Jiang W; Jin Z; Zhou F; Cui J; Wang L; Wang L
    Surg Oncol; 2015 Sep; 24(3):220-5. PubMed ID: 26096373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic and molecular features associated with patient age in gastric cancer.
    Seo JY; Jin EH; Jo HJ; Yoon H; Shin CM; Park YS; Kim N; Jung HC; Lee DH
    World J Gastroenterol; 2015 Jun; 21(22):6905-13. PubMed ID: 26078567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between HER-2, COX-2, p53 and clinicopathologic features in gastric adenocarcinoma. Do these biomarkers have any prognostic significance?
    Ugraş N; Özgün G; Ocakoğlu G; Yerci Ö; Öztürk E
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():176-81. PubMed ID: 25910300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastric adenocarcinoma expressing human epidermal growth factor receptor in South Asian population.
    Shabbir A; Qureshi MA; Khalid AB; Mirza T; Shaikh A; Hasan SM
    Saudi J Gastroenterol; 2018; 24(5):289-293. PubMed ID: 29806596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
    Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
    Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks.
    Ge X; Wang H; Zeng H; Jin X; Sujie A; Xu C; Liu Y; Huang J; Ji Y; Tan Y; Liu T; Hou Y; Qin J; Sun Y; Qin X
    Hum Pathol; 2015 Jun; 46(6):850-7. PubMed ID: 25863425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor expression is an independent poor prognostic factor for human epidermal growth factor receptor 2 positive gastric cancer.
    Hsu JT; Chen TD; Chuang HC; Huang SC; Le PH; Chen TH; Lin CJ; Yeh TS
    J Surg Res; 2017 Feb; 208():40-50. PubMed ID: 27993216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
    Im SA; Kim JW; Kim JS; Kim MA; Jordan B; Pickl M; Han SW; Oh DY; Lee HJ; Kim TY; Kim WH; Yang HK; Bang YJ
    Diagn Mol Pathol; 2011 Jun; 20(2):94-100. PubMed ID: 21532492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical role of HER-2/neu expression in colorectal cancer.
    Pappas A; Lagoudianakis E; Seretis C; Tsiambas E; Koronakis N; Toutouzas K; Katergiannakis V; Manouras A
    J BUON; 2013; 18(1):98-104. PubMed ID: 23613394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
    Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
    J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
    Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ
    J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
    Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
    Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology.
    Sanchez KM; Sweeney CJ; Mass R; Koch MO; Eckert GJ; Geary WA; Baldridge LA; Zhang S; Eble JN; Cheng L
    Cancer; 2002 Oct; 95(8):1650-5. PubMed ID: 12365012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
    Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D
    Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
    Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
    Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
    Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma.
    Lee EY; Cibull ML; Strodel WE; Haley JV
    Arch Pathol Lab Med; 1994 Mar; 118(3):235-9. PubMed ID: 7907854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The significance of NTR1 expression and its correlation with β-catenin and EGFR in gastric cancer.
    Zhou Z; Xie J; Cai Y; Yang S; Chen Y; Wu H
    Diagn Pathol; 2015 Jul; 10():128. PubMed ID: 26215716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
    Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.